
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted…